ZEAL.CO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 09:52):

Stats
Today's Volume	162 282
Average Volume	418 509
Market Cap	38.38B
EPS	DKK0 ( 2024-02-27 )
Next earnings date	( DKK-4.20 ) 2024-05-16
Last Dividend	DKK0 ( N/A )
Next Dividend	DKK0 ( N/A )
P/E	-47.95
ATR14	DKK0.886 (0.15%)

Volume Correlation

Long: -0.14 (neutral)

Short: 0.40 (neutral)

Signal:(46.283) Neutral

Zealand Pharma A/S Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zealand Pharma A/S Correlation - Currency/Commodity

-0.75
( moderate negative )

-0.69
( moderate negative )

-0.55
( weak negative )

-0.68
( moderate negative )

-0.69
( moderate negative )

-0.59
( weak negative )

Zealand Pharma A/S Financials

Annual	2023
Revenue:	DKK342.79M
Gross Profit:	DKK295.31M (86.15 %)
EPS:	DKK-12.44

Q4	2023
Revenue:	DKK23.24M
Gross Profit:	DKK9.22M (39.69 %)
EPS:	DKK-4.54

Q3	2023
Revenue:	DKK295.52M
Gross Profit:	DKK290.36M (98.25 %)
EPS:	DKK1.270

Q2	2023
Revenue:	DKK10.41M
Gross Profit:	DKK5.21M (50.01 %)
EPS:	DKK-5.50

Financial Reports:

No articles found.

Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.